Recap: Coherus BioSciences Q4 Earnings
Portfolio Pulse from Benzinga Insights
Coherus BioSciences (NASDAQ:CHRS) reported Q4 earnings with an EPS of $-0.62, missing estimates by -417.0% against an expected $-0.12. Revenue increased by $46.17 million from the same period last year. Despite beating EPS estimates in Q3 2023, the share price dropped by 30.0% the following day. The company's past earnings performance shows a pattern of fluctuating EPS and revenue figures.
March 13, 2024 | 8:05 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Coherus BioSciences reported a significant miss in Q4 earnings with an EPS of $-0.62 against an expected $-0.12, and a revenue increase of $46.17 million from the previous year.
The significant miss in earnings expectations is likely to negatively impact investor sentiment in the short term, especially considering the company's history of fluctuating performance. The previous quarter's beat on EPS followed by a 30% drop in share price the next day indicates market sensitivity to earnings reports. The increase in revenue may provide some buffer, but the drastic miss in EPS is expected to be the dominant factor affecting the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100